Skip to main content

Table 1 Baseline characteristics of patients with cystic fibrosis at their enrollment in the study and at the start of the placebo or glycine periods

From: Effect of oral glycine on the clinical, spirometric and inflammatory status in subjects with cystic fibrosis: a pilot randomized trial

 

Value at the start of

 

Variable

Value at enrollment

Placebo

Glycine

p*

Gender (male: female)

5:8

Age (years)

13.0 ± 5.4

BMI (kg/m 2 )

15.9 ± 1.5

16.1 ± 1.6

15.8 ± 1.5

0.32

Respiratory rate (breaths/min)

25.3 ± 4.8

22.8 ± 2.6

26.5 ± 5.0

0.015

Questionnaire scorea

11.1 ± 3.6

10.1 ± 3.1

11.1 ± 3.1

0.21

SpO2 (%)

89.5 ± 7.5

92.8 ± 2.8

88.4 ± 7.6

0.032

FVC (% of predicted)

79.1 ± 30.8

84.0 ± 25.2

79.5 ± 28.0

0.34

FEV1 (% of predicted)

65.3 ± 34.4

66.8 ± 30.6

58.7 ± 27.9

0.25

FEV1/FVC (% of predicted)

80.4 ± 16.6

79.8 ± 14.7

74.1 ± 14.0

0.17

Serum glycine (μg/ml)

121.9 ± 23.3

131.8 ± 16.4

153.7 ± 35.1

0.29

  1. Data correspond to frequency (gender) or mean ± standard deviation (n = 13)
  2. Bold font was used to highlight statistically significant differences
  3. *Statistical significance comparing Placebo vs Glycine (Student’s t-test or Mann-Whitney U test)
  4. aEach of five items (cough, sputum, appetite, dyspnea, and energy) was answered in a 5-options Likert scale, ranging from 1 (better) to 5 (worse), for a possible total score value of 5–25
  5. BMI body mass index, CF cystic fibrosis, FEV 1 forced expiratory volume at first second, FVC forced vital capacity